Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
288
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Sangmin LeeDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
View further author information
,
Pinkal DesaiDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Bianca EdirisingheDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Samantha PianelloDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Tania CurcioDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Michael SamuelDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Ellen K. RitchieDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
&
Gail J. RobozDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
 show all
Pages 498-500 | Received 13 May 2020, Accepted 29 Sep 2020, Published online: 10 Oct 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

S. Lee has received research funding from LAM Therapeutics and consulting fees from AstraZeneca, Helsinn, Jazz, Karyopharm, Pharmerit, and Roche Molecular Systems. P. Desai has received research funding from Astex Therapeutics, and consulting fees from Astellas, Cellerant, Celgene, and Agios. E.K. Ritchie has received research funding from Jazz and Pfizer, and consulting fees from Celgene, Novartis, Incyte, Agios, and Roche/Genentech. G.J. Roboz has received research funding from Cellectis and consulting fees from Abbvie, Actinium, Agios, Amphivena, Argenix, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jasper Therapeutics, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, Trovagene.

Additional information

Funding

This study was funded by CTI BioPharma Corp.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.